STOCK TITAN
  1. Home
  2. News
  3. QURE

uniQure N.V. - QURE STOCK NEWS

Welcome to our dedicated page for uniQure N.V. news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on uniQure N.V. stock.

uniQure N.V. (NASDAQ: QURE) is a leading gene therapy company focused on developing transformative therapies for patients suffering from severe genetic and other devastating diseases. Based on its proprietary technology platform, uniQure aims to deliver single-treatment solutions with potentially curative results. The company is dedicated to addressing unmet medical needs in the areas of hemophilia, Huntington's disease, and cardiovascular diseases.

uniQure's core business revolves around advancing a robust pipeline of gene therapies, including its collaboration with Bristol Myers Squibb to develop treatments for cardiovascular diseases. The company’s most notable product, HEMGENIX®, is the first and only gene therapy approved for the treatment of adults with hemophilia B. Recent data from the HOPE-B study presented at the American Society of Hematology Annual Meeting confirmed the long-term efficacy and safety of HEMGENIX®, highlighting its ability to offer elevated and sustained factor IX activity levels for years post-treatment.

The company's financial highlights and strong partnerships underscore its commitment to innovation and leadership in the gene therapy field. uniQure continues to make significant strides with current projects and patient enrollment for new trials expected to begin in the first half of 2024.

With its validated modular technology platform and a dedicated focus on severe genetic diseases, uniQure’s work holds significant promise for transforming patient care and outcomes. The company's latest developments and financial performance are followed closely by investors and the biotechnology community, reflecting its pivotal role in advancing gene therapy solutions.

News

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary

uniQure N.V. reported its first quarter 2024 financial results and recent progress, focusing on advancing AMT-130 for Huntington's disease and initiating new Phase I/II trials for Fabry disease, ALS, and MTLE. The company is on track to interact with the FDA in Q2 2024 and reduce expenses to increase shareholder value. Financially, uniQure's revenues increased to $8.5 million, with a cash position of $555.7 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
earnings
-
News

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
uniQure N.V. (QURE) reported promising clinical updates for AMT-130 in Huntington’s disease, FDA clearance for IND applications, strategic reorganization for cost savings, and a strong cash position. Financially, the company holds approximately $618 million in cash as of December 31, 2023, with revenues of $15.8 million for 2023. However, there was a significant net loss of $308.5 million in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
earnings
-
News

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) announced updated interim data from Phase I/II clinical trials of AMT-130 for Huntington’s disease, showing preserved neurological function and favorable trends in neuronal degradation with generally well-tolerated gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
clinical trial
News

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Rhea-AI Summary
CSL (ASX: CSL; USOTC: CSLLY) announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) gene therapy for hemophilia B. The treatment offers elevated and sustained factor IX activity levels for years, reducing the rate of annual bleeds and the need for regular prophylactic infusions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
News

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) granted 142,300 restricted share units and options to purchase 52,500 ordinary shares to 28 newly hired employees as inducement to commence their employment. Each option has an exercise price of $7.30 per share, with a ten-year term and vesting over four years. The restricted share units vest in three annual installments beginning on December 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
-
News

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

Rhea-AI Summary
uniQure N.V. (NASDAQ: QURE) has received FDA clearance for its gene therapy candidate, AMT-191, for the treatment of Fabry disease. The company's chief medical officer, Walid Abi-Saab, M.D., highlighted the potential of AMT-191 as a one-time treatment incorporating proprietary technology. Patient enrollment for the Phase I/II trial is expected to begin in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
clinical trial
News

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Rhea-AI Summary
uniQure N.V. reported FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy and strategic reorganization to focus on advancing multiple clinical-stage programs, expecting $180 million of cost savings over the next three years. They have a strong cash position of approximately $660 million as of September 30, 2023, which is expected to fund operations into the second quarter of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
earnings
-
News

CSL and uniQure Win 2023 Prix Galien USA Award

Rhea-AI Summary
Global biotechnology leader CSL and uniQure N.V. have won the 2023 Prix Galien USA Award for Best Product for Rare/Orphan Diseases for their gene therapy HEMGENIX®. HEMGENIX is the first and only FDA-approved gene therapy for adults with hemophilia B. It has also received conditional marketing authorization in the European Union and Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
News

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Rhea-AI Summary
uniQure N.V. announces 12 data presentations at the European Society of Gene and Cell Therapy Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
News

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Rhea-AI Summary
uniQure announces strategic reorganization to reduce operating expenses and focus on clinical-stage programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
none

FAQ

What is the current stock price of uniQure N.V. (QURE)?

The current stock price of uniQure N.V. (QURE) is $5.82 as of November 19, 2024.

What is the market cap of uniQure N.V. (QURE)?

The market cap of uniQure N.V. (QURE) is approximately 294.9M.

What is uniQure N.V.?

uniQure N.V. is a gene therapy company focused on developing treatments for severe genetic and other devastating diseases, including hemophilia, Huntington's disease, and cardiovascular diseases.

What is HEMGENIX®?

HEMGENIX® is a gene therapy developed by uniQure for the treatment of adults with hemophilia B. It offers elevated and sustained factor IX activity levels following a one-time infusion.

What are the recent achievements of uniQure?

Recent achievements include the long-term efficacy and safety data from the pivotal HOPE-B study for HEMGENIX®, showing sustained factor IX activity levels and reduced annual bleeding rates for hemophilia B patients.

What are uniQure's current projects?

uniQure is currently advancing a pipeline of gene therapies, with new patient enrollment for trials expected to begin in the first half of 2024.

Who are uniQure's partners?

uniQure collaborates with Bristol Myers Squibb for the development of gene therapies for cardiovascular diseases.

Where is uniQure N.V. listed?

uniQure N.V. is listed on the NASDAQ stock exchange under the ticker symbol QURE.

What is the focus of uniQure's research and development?

uniQure focuses on developing gene therapies for severe genetic diseases, leveraging its modular and validated technology platform.

How does HEMGENIX® work?

HEMGENIX® uses a non-infectious viral vector to deliver genetic instructions to liver cells, enabling the body to produce stable levels of factor IX, which is deficient in hemophilia B patients.

What are the financial highlights of uniQure?

uniQure's financial highlights reflect its robust pipeline and ongoing advancements in gene therapy, supported by strategic partnerships and investor interest.

What is the significance of the HOPE-B study?

The HOPE-B study provides long-term follow-up data demonstrating the efficacy and safety of HEMGENIX®, reinforcing its potential as a groundbreaking treatment for hemophilia B.

Stock QURE logo
uniQure N.V.

Nasdaq:QURE

QURE Rankings

#3546 Ranked by Market Cap
N/A Ranked by Dividends

QURE Stock Data

294.90M
43.89M
9.23%
81.95%
6.87%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AMSTERDAM